+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Rosacea Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 386 Pages
  • January 2024
  • Region: Global
  • Fairfield Market Research
  • ID: 5925049
Description Jump to:
The global rosacea therapeutics market, valued at US$ 4.3 billion in 2024, is projected to exhibit remarkable growth and reach a staggering US$ 7.2 billion by 2031. As the demand for rosacea therapeutic delivery systems and drugs continues to surge, key players in the market are set to benefit from untapped opportunities.

Rosacea Therapy Faces Need for More Effective Drugs

The current landscape of rosacea treatment options primarily offers short-term palliative relief, often utilizing antibiotics like doxycycline and topical metronidazole or azelaic acid as first-line agents. However, these treatments do not address the root cause of the disease, creating an unmet medical need for more effective drugs that target the underlying cause of rosacea.

While the research and development pipeline for rosacea therapeutics lags behind that of other diseases, initiatives such as the National Rosacea Society's research awards program are granting funds to support scientific studies aimed at uncovering the inflammatory cycle, a key underlying factor in the condition. This funding serves as a catalyst for researchers and scientists to develop novel medicines for rosacea treatment.

Challenges to Rosacea Therapeutics Growth

Despite its prevalence, rosacea is generally not life-threatening, contributing to a low treatment rate due to perceptions of treatment ineffectiveness. Lack of effective diagnostic tests results in false negatives, hindering the rosacea treatment products market.

The non-life-threatening nature of rosacea, coupled with the poor efficacy of existing treatments, has led to stiff competition from alternative treatments that are often ineffective. Rosacea patients frequently turn to non-prescription skincare products, such as mild cleansers, moisturizers, and sunscreens, further challenging the rosacea therapeutics market.

Country-wise Insights

U.S. Dominates Due to High Awareness: The U.S. leads the North America rosacea therapeutics market in 2023, driven by a high level of awareness among patients and end users about rosacea and its treatment options. Additionally, the country's substantial rosacea patient population contributes to the strong demand for rosacea therapeutics.

Germany's High Rate of Diagnosis and Treatment: Germany stands out with a high rate of treatment and diagnosis, substantial healthcare expenditure, and numerous collaborations driving market growth. Quality healthcare services, an aging population, and rising skin diseases bolster demand for rosacea treatment products.

China Emerges as a Promising Market: The China rosacea therapeutics market commands over 50% of the East Asian market share. The rising incidence of rosacea in China, as reported by the Indian Journal of Dermatology, Venereology, and Leprology in 2020, fuels market expansion.

Competitive Landscape

Key players in the rosacea therapeutics market are focusing on expanding product distribution in high-profit markets, showcasing products at scientific meetings and conferences, and forming strategic partnerships with suppliers to strengthen their market presence.

Key Companies Profiled:

  • Lupin Ltd
  • Dr. Reddy's Laboratories Ltd
  • VIATRIS (Mylan N.V.)
  • Ajanta Pharma Ltd
  • Cipla Ltd
  • Gary Pharmaceuticals P Limited
  • Glenmark Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Mission Pharmacal
  • Sanofi SA
  • VYNE Therapeutics
  • Galderma
  • Bayer AG
  • Bausch Health Companies Inc.
  • Hovione
  • PruGen Pharmaceuticals
  • AbbVie, Inc.
  • Eckson Labs
  • Sandoz Spa
  • Abigail Care Pharmaceutical
  • Pfizer Inc.
  • Johnson & Johnson (Janssen Pharmaceuticals, Inc.)

Key Segments in Rosacea Therapeutics Industry Survey

Rosacea Therapeutics Market by Disease Type:

  • Erythematotelangiectatic Rosacea
  • Papulopustular Rosacea
  • Ocular Rosacea
  • Phymatous Rosacea

Rosacea Therapeutics Market by Drug Class:

  • Antibiotics
  • Immunosuppressants
  • Corticosteroids
  • Others

Rosacea Therapeutics Market by Treatment Type:

  • Antibiotics
  • Clindamycin
  • Erythromycin/ Clarithromycin
  • Metronidazole
  • Doxycycline
  • Tetracycline
  • Lymecycline
  • Minocycline
  • Topical Treatment
  • Sodium Sulfacetamide
  • Azelaic acid
  • Metronidazole
  • Clindamycin
  • Erythromycin
  • Tretinoin
  • Oxymetazoline
  • Isotretinoin
  • Tazarotene
  • Adapalene
  • Steroid Creams
  • Eye Drops and Lubricants
  • Other Drugs Including Methotrexate and Ivermectin
  • Laser therapy

Rosacea Therapeutics Market by Route of Administration:

  • Oral Rosacea Treatment
  • Topical Rosacea Treatment
  • Others

Rosacea Therapeutics Market by Distribution Channel:

  • Institutional Sales
  • Hospitals
  • Specialty Clinics
  • Academic and Research Institutes
  • Retail Sales
  • Retail Pharmacies
  • Drug Stores
  • Online Sales

Rosacea Therapeutics Market by Region:

  • North America Rosacea Therapeutics Market
  • Latin America Rosacea Therapeutics Market
  • Europe Rosacea Therapeutics Market
  • South Asia Rosacea Therapeutics Market
  • East Asia Rosacea Therapeutics Market
  • Oceania Rosacea Therapeutics Market
  • Middle East & Africa Rosacea Therapeutics Market


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Rosacea Therapeutics Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Rosacea Therapeutics Market Outlook, 2018 - 2031
3.1. Global Rosacea Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Erythematotelangiectatic Rosacea
3.1.1.2. Papulopustular Rosacea
3.1.1.3. Ocular Rosacea
3.1.1.4. Phymatous Rosacea
3.2. Global Rosacea Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Antibiotics
3.2.1.2. Immunosuppressants
3.2.1.3. Corticosteroids
3.2.1.4. Others
3.3. Global Rosacea Therapeutics Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Antibiotics
3.3.1.1.1. Clindamycin
3.3.1.1.2. Erythromycin/ Clarithromycin
3.3.1.1.3. Metronidazole
3.3.1.1.4. Doxycycline
3.3.1.1.5. Tetracycline
3.3.1.1.6. Lymecycline
3.3.1.1.7. Minocycline
3.3.1.2. Topical Treatment
3.3.1.2.1. Sodium Sulfacetamide
3.3.1.2.2. Azelaic acid
3.3.1.2.3. Metronidazole
3.3.1.2.4. Clindamycin
3.3.1.2.5. Erythromycin
3.3.1.2.6. Tretinoin
3.3.1.2.7. Oxymetazoline
3.3.1.2.8. Isotretinoin
3.3.1.2.9. Tazarotene
3.3.1.2.10. Adapalene
3.3.1.2.11. Steroid Creams
3.3.1.3. Eye Drops and Lubricants
3.3.1.4. Other Drugs Including Methotrexate and Ivermectin
3.3.1.5. Laser therapy
3.4. Global Rosacea Therapeutics Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. Oral Rosacea Treatment
3.4.1.2. Topical Rosacea Treatment
3.4.1.3. Others
3.5. Global Rosacea Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
3.5.1. Key Highlights
3.5.1.1. Institutional Sales
3.5.1.1.1. Hospitals
3.5.1.1.2. Specialty Clinics
3.5.1.1.3. Academic and Research Institutes
3.5.1.2. Retail Sales
3.5.1.2.1. Retail Pharmacies
3.5.1.2.2. Drug Stores
3.5.1.3. Online Sales
3.6. Global Rosacea Therapeutics Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.6.1. Key Highlights
3.6.1.1. North America
3.6.1.2. Europe
3.6.1.3. Asia Pacific
3.6.1.4. Latin America
3.6.1.5. Middle East & Africa
4. North America Rosacea Therapeutics Market Outlook, 2018 - 2031
4.1. North America Rosacea Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Erythematotelangiectatic Rosacea
4.1.1.2. Papulopustular Rosacea
4.1.1.3. Ocular Rosacea
4.1.1.4. Phymatous Rosacea
4.2. North America Rosacea Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Antibiotics
4.2.1.2. Immunosuppressants
4.2.1.3. Corticosteroids
4.2.1.4. Others
4.3. North America Rosacea Therapeutics Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Antibiotics
4.3.1.1.1. Clindamycin
4.3.1.1.2. Erythromycin/ Clarithromycin
4.3.1.1.3. Metronidazole
4.3.1.1.4. Doxycycline
4.3.1.1.5. Tetracycline
4.3.1.1.6. Lymecycline
4.3.1.1.7. Minocycline
4.3.1.2. Topical Treatment
4.3.1.2.1. Sodium Sulfacetamide
4.3.1.2.2. Azelaic acid
4.3.1.2.3. Metronidazole
4.3.1.2.4. Clindamycin
4.3.1.2.5. Erythromycin
4.3.1.2.6. Tretinoin
4.3.1.2.7. Oxymetazoline
4.3.1.2.8. Isotretinoin
4.3.1.2.9. Tazarotene
4.3.1.2.10. Adapalene
4.3.1.2.11. Steroid Creams
4.3.1.3. Eye Drops and Lubricants
4.3.1.4. Other Drugs Including Methotrexate and Ivermectin
4.3.1.5. Laser therapy
4.4. North America Rosacea Therapeutics Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. Oral Rosacea Treatment
4.4.1.2. Topical Rosacea Treatment
4.4.1.3. Others
4.5. North America Rosacea Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.5.1. Key Highlights
4.5.1.1. Institutional Sales
4.5.1.1.1. Hospitals
4.5.1.1.2. Specialty Clinics
4.5.1.1.3. Academic and Research Institutes
4.5.1.2. Retail Sales
4.5.1.2.1. Retail Pharmacies
4.5.1.2.2. Drug Stores
4.5.1.3. Online Sales
4.5.2. BPS Analysis/Market Attractiveness Analysis
4.6. North America Rosacea Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.6.1. Key Highlights
4.6.1.1. U.S. Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
4.6.1.2. U.S. Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
4.6.1.3. U.S. Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
4.6.1.4. U.S. Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
4.6.1.5. U.S. Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.6.1.6. Canada Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
4.6.1.7. Canada Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
4.6.1.8. Canada Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
4.6.1.9. Canada Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
4.6.1.10. Canada Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.6.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Rosacea Therapeutics Market Outlook, 2018 - 2031
5.1. Europe Rosacea Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Erythematotelangiectatic Rosacea
5.1.1.2. Papulopustular Rosacea
5.1.1.3. Ocular Rosacea
5.1.1.4. Phymatous Rosacea
5.2. Europe Rosacea Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Antibiotics
5.2.1.2. Immunosuppressants
5.2.1.3. Corticosteroids
5.2.1.4. Others
5.3. Europe Rosacea Therapeutics Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Antibiotics
5.3.1.1.1. Clindamycin
5.3.1.1.2. Erythromycin/ Clarithromycin
5.3.1.1.3. Metronidazole
5.3.1.1.4. Doxycycline
5.3.1.1.5. Tetracycline
5.3.1.1.6. Lymecycline
5.3.1.1.7. Minocycline
5.3.1.2. Topical Treatment
5.3.1.2.1. Sodium Sulfacetamide
5.3.1.2.2. Azelaic acid
5.3.1.2.3. Metronidazole
5.3.1.2.4. Clindamycin
5.3.1.2.5. Erythromycin
5.3.1.2.6. Tretinoin
5.3.1.2.7. Oxymetazoline
5.3.1.2.8. Isotretinoin
5.3.1.2.9. Tazarotene
5.3.1.2.10. Adapalene
5.3.1.2.11. Steroid Creams
5.3.1.3. Eye Drops and Lubricants
5.3.1.4. Other Drugs Including Methotrexate and Ivermectin
5.3.1.5. Laser therapy
5.4. Europe Rosacea Therapeutics Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Oral Rosacea Treatment
5.4.1.2. Topical Rosacea Treatment
5.4.1.3. Others
5.5. Europe Rosacea Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.5.1. Key Highlights
5.5.1.1. Institutional Sales
5.5.1.1.1. Hospitals
5.5.1.1.2. Specialty Clinics
5.5.1.1.3. Academic and Research Institutes
5.5.1.2. Retail Sales
5.5.1.2.1. Retail Pharmacies
5.5.1.2.2. Drug Stores
5.5.1.3. Online Sales
5.5.2. BPS Analysis/Market Attractiveness Analysis
5.6. Europe Rosacea Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.6.1. Key Highlights
5.6.1.1. Germany Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.6.1.2. Germany Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.6.1.3. Germany Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.6.1.4. Germany Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.6.1.5. Germany Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.1.6. U.K. Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.6.1.7. U.K. Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.6.1.8. U.K. Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.6.1.9. U.K. Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.6.1.10. U.K. Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.1.11. France Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.6.1.12. France Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.6.1.13. France Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.6.1.14. France Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.6.1.15. France Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.1.16. Italy Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.6.1.17. Italy Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.6.1.18. Italy Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.6.1.19. Italy Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.6.1.20. Italy Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.1.21. Turkey Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.6.1.22. Turkey Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.6.1.23. Turkey Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.6.1.24. Turkey Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.6.1.25. Turkey Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.1.26. Russia Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.6.1.27. Russia Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.6.1.28. Russia Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.6.1.29. Russia Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.6.1.30. Russia Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.1.31. Rest of Europe Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
5.6.1.32. Rest of Europe Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
5.6.1.33. Rest of Europe Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
5.6.1.34. Rest of Europe Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.6.1.35. Rest of Europe Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.6.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Rosacea Therapeutics Market Outlook, 2018 - 2031
6.1. Asia Pacific Rosacea Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Erythematotelangiectatic Rosacea
6.1.1.2. Papulopustular Rosacea
6.1.1.3. Ocular Rosacea
6.1.1.4. Phymatous Rosacea
6.2. Asia Pacific Rosacea Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Antibiotics
6.2.1.2. Immunosuppressants
6.2.1.3. Corticosteroids
6.2.1.4. Others
6.3. Asia Pacific Rosacea Therapeutics Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Antibiotics
6.3.1.1.1. Clindamycin
6.3.1.1.2. Erythromycin/ Clarithromycin
6.3.1.1.3. Metronidazole
6.3.1.1.4. Doxycycline
6.3.1.1.5. Tetracycline
6.3.1.1.6. Lymecycline
6.3.1.1.7. Minocycline
6.3.1.2. Topical Treatment
6.3.1.2.1. Sodium Sulfacetamide
6.3.1.2.2. Azelaic acid
6.3.1.2.3. Metronidazole
6.3.1.2.4. Clindamycin
6.3.1.2.5. Erythromycin
6.3.1.2.6. Tretinoin
6.3.1.2.7. Oxymetazoline
6.3.1.2.8. Isotretinoin
6.3.1.2.9. Tazarotene
6.3.1.2.10. Adapalene
6.3.1.2.11. Steroid Creams
6.3.1.3. Eye Drops and Lubricants
6.3.1.4. Other Drugs Including Methotrexate and Ivermectin
6.3.1.5. Laser therapy
6.4. Asia Pacific Rosacea Therapeutics Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. Oral Rosacea Treatment
6.4.1.2. Topical Rosacea Treatment
6.4.1.3. Others
6.5. Asia Pacific Rosacea Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.5.1. Key Highlights
6.5.1.1. Institutional Sales
6.5.1.1.1. Hospitals
6.5.1.1.2. Specialty Clinics
6.5.1.1.3. Academic and Research Institutes
6.5.1.2. Retail Sales
6.5.1.2.1. Retail Pharmacies
6.5.1.2.2. Drug Stores
6.5.1.3. Online Sales
6.5.2. BPS Analysis/Market Attractiveness Analysis
6.6. Asia Pacific Rosacea Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.6.1. Key Highlights
6.6.1.1. China Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
6.6.1.2. China Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
6.6.1.3. China Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.6.1.4. China Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.6.1.5. China Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.6.1.6. Japan Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
6.6.1.7. Japan Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
6.6.1.8. Japan Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.6.1.9. Japan Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.6.1.10. Japan Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.6.1.11. South Korea Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
6.6.1.12. South Korea Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
6.6.1.13. South Korea Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.6.1.14. South Korea Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.6.1.15. South Korea Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.6.1.16. India Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
6.6.1.17. India Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
6.6.1.18. India Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.6.1.19. India Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.6.1.20. India Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.6.1.21. Southeast Asia Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
6.6.1.22. Southeast Asia Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
6.6.1.23. Southeast Asia Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.6.1.24. Southeast Asia Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.6.1.25. Southeast Asia Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.6.1.26. Rest of Asia Pacific Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
6.6.1.27. Rest of Asia Pacific Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
6.6.1.28. Rest of Asia Pacific Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
6.6.1.29. Rest of Asia Pacific Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.6.1.30. Rest of Asia Pacific Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.6.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Rosacea Therapeutics Market Outlook, 2018 - 2031
7.1. Latin America Rosacea Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Erythematotelangiectatic Rosacea
7.1.1.2. Papulopustular Rosacea
7.1.1.3. Ocular Rosacea
7.1.1.4. Phymatous Rosacea
7.2. Latin America Rosacea Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
7.2.1. Key Highlights
7.2.1.1. Antibiotics
7.2.1.2. Immunosuppressants
7.2.1.3. Corticosteroids
7.2.1.4. Others
7.3. Latin America Rosacea Therapeutics Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Antibiotics
7.3.1.1.1. Clindamycin
7.3.1.1.2. Erythromycin/ Clarithromycin
7.3.1.1.3. Metronidazole
7.3.1.1.4. Doxycycline
7.3.1.1.5. Tetracycline
7.3.1.1.6. Lymecycline
7.3.1.1.7. Minocycline
7.3.1.2. Topical Treatment
7.3.1.2.1. Sodium Sulfacetamide
7.3.1.2.2. Azelaic acid
7.3.1.2.3. Metronidazole
7.3.1.2.4. Clindamycin
7.3.1.2.5. Erythromycin
7.3.1.2.6. Tretinoin
7.3.1.2.7. Oxymetazoline
7.3.1.2.8. Isotretinoin
7.3.1.2.9. Tazarotene
7.3.1.2.10. Adapalene
7.3.1.2.11. Steroid Creams
7.3.1.3. Eye Drops and Lubricants
7.3.1.4. Other Drugs Including Methotrexate and Ivermectin
7.3.1.5. Laser therapy
7.4. Latin America Rosacea Therapeutics Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Oral Rosacea Treatment
7.4.1.2. Topical Rosacea Treatment
7.4.1.3. Others
7.5. Latin America Rosacea Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.5.1. Key Highlights
7.5.1.1. Institutional Sales
7.5.1.1.1. Hospitals
7.5.1.1.2. Specialty Clinics
7.5.1.1.3. Academic and Research Institutes
7.5.1.2. Retail Sales
7.5.1.2.1. Retail Pharmacies
7.5.1.2.2. Drug Stores
7.5.1.3. Online Sales
7.5.2. BPS Analysis/Market Attractiveness Analysis
7.6. Latin America Rosacea Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.6.1. Key Highlights
7.6.1.1. Brazil Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
7.6.1.2. Brazil Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
7.6.1.3. Brazil Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
7.6.1.4. Brazil Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
7.6.1.5. Brazil Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.6.1.6. Mexico Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
7.6.1.7. Mexico Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
7.6.1.8. Mexico Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
7.6.1.9. Mexico Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
7.6.1.10. Mexico Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.6.1.11. Argentina Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
7.6.1.12. Argentina Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
7.6.1.13. Argentina Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
7.6.1.14. Argentina Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
7.6.1.15. Argentina Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.6.1.16. Rest of Latin America Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
7.6.1.17. Rest of Latin America Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
7.6.1.18. Rest of Latin America Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
7.6.1.19. Rest of Latin America Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
7.6.1.20. Rest of Latin America Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.6.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Rosacea Therapeutics Market Outlook, 2018 - 2031
8.1. Middle East & Africa Rosacea Therapeutics Market Outlook, by Disease Type, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Erythematotelangiectatic Rosacea
8.1.1.2. Papulopustular Rosacea
8.1.1.3. Ocular Rosacea
8.1.1.4. Phymatous Rosacea
8.2. Middle East & Africa Rosacea Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Antibiotics
8.2.1.2. Immunosuppressants
8.2.1.3. Corticosteroids
8.2.1.4. Others
8.3. Middle East & Africa Rosacea Therapeutics Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Antibiotics
8.3.1.1.1. Clindamycin
8.3.1.1.2. Erythromycin/ Clarithromycin
8.3.1.1.3. Metronidazole
8.3.1.1.4. Doxycycline
8.3.1.1.5. Tetracycline
8.3.1.1.6. Lymecycline
8.3.1.1.7. Minocycline
8.3.1.2. Topical Treatment
8.3.1.2.1. Sodium Sulfacetamide
8.3.1.2.2. Azelaic acid
8.3.1.2.3. Metronidazole
8.3.1.2.4. Clindamycin
8.3.1.2.5. Erythromycin
8.3.1.2.6. Tretinoin
8.3.1.2.7. Oxymetazoline
8.3.1.2.8. Isotretinoin
8.3.1.2.9. Tazarotene
8.3.1.2.10. Adapalene
8.3.1.2.11. Steroid Creams
8.3.1.3. Eye Drops and Lubricants
8.3.1.4. Other Drugs Including Methotrexate and Ivermectin
8.3.1.5. Laser therapy
8.4. Middle East & Africa Rosacea Therapeutics Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. Oral Rosacea Treatment
8.4.1.2. Topical Rosacea Treatment
8.4.1.3. Others
8.5. Middle East & Africa Rosacea Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.5.1. Key Highlights
8.5.1.1. Institutional Sales
8.5.1.1.1. Hospitals
8.5.1.1.2. Specialty Clinics
8.5.1.1.3. Academic and Research Institutes
8.5.1.2. Retail Sales
8.5.1.2.1. Retail Pharmacies
8.5.1.2.2. Drug Stores
8.5.1.3. Online Sales
8.5.2. BPS Analysis/Market Attractiveness Analysis
8.6. Middle East & Africa Rosacea Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.6.1. Key Highlights
8.6.1.1. GCC Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
8.6.1.2. GCC Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
8.6.1.3. GCC Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.6.1.4. GCC Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.6.1.5. GCC Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.6.1.6. South Africa Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
8.6.1.7. South Africa Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
8.6.1.8. South Africa Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.6.1.9. South Africa Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.6.1.10. South Africa Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.6.1.11. Egypt Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
8.6.1.12. Egypt Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
8.6.1.13. Egypt Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.6.1.14. Egypt Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.6.1.15. Egypt Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.6.1.16. Nigeria Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
8.6.1.17. Nigeria Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
8.6.1.18. Nigeria Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.6.1.19. Nigeria Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.6.1.20. Nigeria Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.6.1.21. Rest of Middle East & Africa Rosacea Therapeutics Market by Disease Type, Value (US$ Bn), 2018 - 2031
8.6.1.22. Rest of Middle East & Africa Rosacea Therapeutics Market by Drug Class, Value (US$ Bn), 2018 - 2031
8.6.1.23. Rest of Middle East & Africa Rosacea Therapeutics Market by Treatment Type, Value (US$ Bn), 2018 - 2031
8.6.1.24. Rest of Middle East & Africa Rosacea Therapeutics Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.6.1.25. Rest of Middle East & Africa Rosacea Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.6.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Disease Type vs Drug Class Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Lupin Ltd
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Dr. Reddy's Laboratories Ltd
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Ajanta Pharma Ltd
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Cipla Ltd
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Gary Pharmaceuticals P Limited
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Glenmark Pharmaceuticals
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Teva Pharmaceutical Industries Ltd.
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Mission Pharmacal
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Sanofi SA
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. VYNE Therapeutics
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
9.4.11. Galderma
9.4.11.1. Company Overview
9.4.11.2. Product Portfolio
9.4.11.3. Financial Overview
9.4.11.4. Business Strategies and Development
9.4.12. Bayer AG
9.4.12.1. Company Overview
9.4.12.2. Product Portfolio
9.4.12.3. Financial Overview
9.4.12.4. Business Strategies and Development
9.4.13. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
9.4.13.1. Company Overview
9.4.13.2. Product Portfolio
9.4.13.3. Financial Overview
9.4.13.4. Business Strategies and Development
9.4.14. Bausch Health Companies Inc.
9.4.14.1. Company Overview
9.4.14.2. Product Portfolio
9.4.14.3. Financial Overview
9.4.14.4. Business Strategies and Development
9.4.15. Hovione
9.4.15.1. Company Overview
9.4.15.2. Product Portfolio
9.4.15.3. Financial Overview
9.4.15.4. Business Strategies and Development
9.4.16. PruGen Pharmaceuticals
9.4.16.1. Company Overview
9.4.16.2. Product Portfolio
9.4.16.3. Financial Overview
9.4.16.4. Business Strategies and Development
9.4.17. AbbVie, Inc.
9.4.17.1. Company Overview
9.4.17.2. Product Portfolio
9.4.17.3. Financial Overview
9.4.17.4. Business Strategies and Development
9.4.18. Eckson Labs
9.4.18.1. Company Overview
9.4.18.2. Product Portfolio
9.4.18.3. Financial Overview
9.4.18.4. Business Strategies and Development
9.4.19. Sandoz Spa
9.4.19.1. Company Overview
9.4.19.2. Product Portfolio
9.4.19.3. Financial Overview
9.4.19.4. Business Strategies and Development
9.4.20. Abigail Care Pharmaceutical
9.4.20.1. Company Overview
9.4.20.2. Product Portfolio
9.4.20.3. Financial Overview
9.4.20.4. Business Strategies and Development
9.4.21. Pfizer Inc.
9.4.21.1. Company Overview
9.4.21.2. Product Portfolio
9.4.21.3. Financial Overview
9.4.21.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Lupin Ltd
  • Dr. Reddy's Laboratories Ltd
  • VIATRIS (Mylan N.V.)
  • Ajanta Pharma Ltd
  • Cipla Ltd
  • Gary Pharmaceuticals P Limited
  • Glenmark Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Mission Pharmacal
  • Sanofi SA
  • VYNE Therapeutics
  • Galderma
  • Bayer AG
  • Bausch Health Companies Inc.
  • Hovione
  • PruGen Pharmaceuticals
  • AbbVie, Inc.
  • Eckson Labs
  • Sandoz Spa
  • Abigail Care Pharmaceutical
  • Pfizer Inc.
  • Johnson & Johnson (Janssen Pharmaceuticals, Inc.)

Methodology

Loading
LOADING...

Related Topics

Related Reports

Rosacea Medicine Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Rosacea Medicine Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 110 Pages
  • Global
From
Rosacea Treatment Market Report by Type, Drug Class, Route of Administration, Distribution Channel, End User, and Region 2024-2032 - Product Image

Rosacea Treatment Market Report by Type, Drug Class, Route of Administration, Distribution Channel, End User, and Region 2024-2032

  • Report
  • 148 Pages
  • Global
From
Rosacea Treatment Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Rosacea Treatment Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 84 Pages
  • Global
From
Global Rosacea Treatment Market 2024-2028 - Product Image

Global Rosacea Treatment Market 2024-2028

  • Report
  • 170 Pages
  • Global
From
Rosacea - Pipeline Insight, 2024 - Product Image

Rosacea - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From

About the Rosacea Drug Market

The Rosacea Drug market is a subset of the Dermatological Drugs market, which includes medications used to treat skin conditions. Rosacea is a chronic skin condition that causes redness, flushing, and visible blood vessels on the face. Common treatments for rosacea include topical and oral antibiotics, topical retinoids, and laser and light therapies. These treatments can reduce inflammation, redness, and the appearance of blood vessels. The Rosacea Drug market is expected to grow in the coming years due to increasing awareness of the condition and the availability of new treatments. Additionally, the increasing prevalence of rosacea in the aging population is expected to drive market growth. Some companies in the Rosacea Drug market include Galderma, Allergan, Bayer, and Novartis. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.